Indirect comparison of different adjuvant chemotherapies for stage II-III gastric cancer after D2 gastrectomy in Asian patients.
- Author:
Zhi-min JIANG
1
;
Ying WEI
;
Yuan-dong ZHANG
;
Si-wei ZHOU
;
Qiong YANG
;
De-rong XIE
Author Information
- Publication Type:Journal Article
- MeSH: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; analogs & derivatives; Fluorouracil; analogs & derivatives; Humans; Postoperative Care; Randomized Controlled Trials as Topic; Stomach Neoplasms; drug therapy; surgery; Treatment Outcome
- From: Chinese Journal of Gastrointestinal Surgery 2013;16(6):534-537
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare efficacy of different adjuvant chemotherapy regimens for stage II-III gastric cancer after D2 gastrectomy in Asian patients.
METHODSAssociated literatures were searched through electronic databases and hand-searching. Prospective randomized clinical trials (RCTs) comparing adjuvant chemotherapy after D2 gastrectomy with surgery alone were included in the study. Overall survival and disease-free survival were chosen as the endpoints. Relative hazard was analyzed by Bucher adjusted indirect comparison.
RESULTSTwo RCTs were selected, including comparison between S-1 versus surgery alone and comparison between XELOX versus surgery alone. There was no statistical difference in overall survival between the two regimens (HR=0.94, 95%CI:0.62-1.44, P=0.79). The recurrence risk of S-1 was slightly higher as compared to XELOX, but no statistical difference was found (HR=1.11, 95%CI:0.80-1.53, P=0.54).
CONCLUSIONThe adjuvant chemotherapy with S-1 is similar to XELOX for stage II-III gastric cancer after D2 gastrectomy in Asian patients.
